Trial Profile
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2013
Price :
$35
*
At a glance
- Drugs PEK fusion protein vaccine (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Adverse reactions
- 25 Jun 2013 New trial record